Psybio Therapeutics Corp. Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds
June 22, 2021 at 07:43 am EDT
PsyBio Therapeutics Corp. has initiated its first, European pilot scale batch manufacturing of its psychedelic portfolio of compounds
with the proprietary biosynthetic formulation of psilocybin in collaboration with Biose Industrie ("Biose"), an expert in commercializing pharmaceutical products based on live bacterial production, to prepare products and substances for ongoing regulatory evaluation.